



**UNIVERSITI PUTRA MALAYSIA**

**TOXIN ANTITOXIN SYSTEM AS AN ANTIMICROBIAL TARGET FOR  
ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS**

**SOBHAN GHAFOURYAN**

**FPSK(p) 2014 17**



**TOXIN ANTITOXIN SYSTEM AS AN ANTIMICROBIAL TARGET FOR  
ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS**

By

**SOBHAN GHAFOURYAN**

**Thesis submitted to the School of Graduate Studies, Universiti Putra  
Malaysia, in Fulfilment of the Requirement for the Degree of Doctor of  
Philosophy**

**February 2014**

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in  
fulfilment of the requirement for the degree of Doctor of Philosophy

## **TOXIN ANTITOXIN SYSTEM AS AN ANTIMICROBIAL TARGET FOR ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS**

By

**SOBHAN GHAFOURYAN**

**February 2014**

**Chairman: Professor Zamberi bin Sekawi**  
**Faculty: Medicine and Health Sciences**

Antibiotic-resistant bacteria have become a global concern and new strategies to control pathogenic bacteria are urgently needed. Toxin antitoxin (TA) system is defined as a regulator system consist of toxin that neutralized by cognate antitoxin. In theory, activation of the toxin or inhibition of the antitoxin within a bacterial TA system could provide a potent new antibiotic therapy. TA systems can increase pathogen stress tolerance and certain TA loci have be characterized in a small number of Methicillin Resistant *Staphylococcus aureus* (MRSA), Vancomycin Resistant Enterococcus (VRE), *E. coli*, and *Pseudomonas aeruginosa*. Here it is determined the prevalence of TA system in a large number of independently isolated clinical isolates of antibiotic resistant *S. aureus* from diverse locations, then functionality of dominant TA system is evaluated and the antitoxin is subjected for silencing by antiMazE Peptide Nucleotide Acid (PNA) subsequently the suicide of bacteria by toxin is determined. To evaluate potential TA loci as therapeutic targets, it was screened the plasmid and chromosome sequences of 1000 clinical isolates of *S. aureus* from Milad hospital in Iran and 60 MRSA clinical isolates from Hospital Kuala Lumpur (HKL) in Malaysia for the presence of TA loci. Plasmid-borne *MazEF* TA loci were present in all tested, antibiotic resistant *S. aureus* strains in Iran and MRSA in Malaysia while when DNA were subjected as template, 21.2% of Milad hospital and 22.6% of HKL isolates were positive for *MazEF* TA system. In addition, plasmid transformation confirmed *MazEF* TA loci harboured on plasmid. Additionally, RT-PCR analysis revealed that the transcripts were produced from *MazEF* TA loci, suggesting that these loci are functional in the clinical isolates. Toxin transcript expression levels were increase when bacteria were grown under stressful conditions. Furthermore, cellular ATP levels are decreased consistent with *MazF* toxin expression and activity. The ATP

results were confirmed by turbidity analysis. To activate toxin expression, it was targeted the *MazE* antitoxin mRNA using peptide nucleic acid (PNA) oligomers. The anti-*MazE* oligomers were bactericidal against drug-resistant *S. aureus* containing *MazEF* and did not inhibit strains lacking *MazEF*. Therefore, *MazEF* TA loci are widespread in drug-resistant strains of *S. aureus* and are plasmid-borne, and activation of toxin activity by silencing of the antitoxin gene provides a means to selectively kill drug resistant strains.

**Keywords:** Toxin antitoxin system, *MazEF*, *Staphylococcus aureus*, Peptide Nucleotide Acid.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia  
sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

## **SISTEM ANTITOKSIN TOKSIN BAGAI SASARAN ANTIMIKROBIAL UNTUK STAPHYLOCOCCUS AUREUS PERINTANG ANTIBIOTIK**

Oleh

**SOBHAN GHAFOURIAN**

**February 2014**

**Pengerusi: Professor Zamberi bin Sekawi**  
**Fakulti: Perubatan dan Sains Kesihatan**

Bakteria yang mempunyai ketahanan antibiotik menjadi perhatian global masa kini dan strategi baru amat diperlukan dalam mengawal bakteria yang patogenik. Toksin-antitoksin sistem (TA) ditakrifkan sebagai satu system pengawalan yang terdiri daripada toksin yang dineutralkan oleh antitoksin berpadanan. Secara teorinya, pengaktifan toksin or perencatan antitoksin di kalangan toksin-antitoksin bakteria membolehkan penghasilan antibiotik baru yang berkesan. Sistem TA boleh meningkatkan tekanan toleransi pada patogen dan lokus TA tertentu telah dikategorikan dalam sebilangan kecil Methicillin Resistant *Staphylococcus aureus* (MRSA), Vancomycin Resistant *Enterococcus* (VRE), *Escherichia coli*, and *Pseudomonas aeruginosa*. Kelaziman system TA dalam jumlah yang besar dari sampel klinikal MRSA dari pelbagai lokasi telah ditentukan, kemudian fungsi dominan sistem TA dinilai dan antitoksin adalah tertakluk untuk penyenyapan oleh *antiMazE* Asid Nukleotida Peptida, seterusnya bakteria yang matidisebabkan antotoksin ditentukan.

Bagi menilai potensi lokus TA sebagai target terapi, plasmid and jujukan kromosom telah diuji terhadap 1000 isolat klinikal, di mana isolate ini adalah *S. aureus* yang telah diambil dari Hospital Milad di Iran. Selain itu juga, sebanyak 60 isolat klinikal terdiri daripada MRSA telah diambil dari Hospital Kuala Lumpur (HKL) di Malaysia bagi mengesan lokus TA.

Plasmid-borne lokus TA *MazEF* telah dikesan dalam semua ujikaji sama ada dalam ketahanan terhadap antibiotik bagi sub-species *S. aureus* dari Iran mahupun MRSA di Malaysia. Sementara itu, sebanyak 21.2% isolat dari hospital Milad dan 22.6% isolat dari HKL telah dikesan positif untuk system TA *MazEF*. Tambahan lagi, transformasi plasmid mengesahkan lokus *MazEF* telah ditumpukan ke dalam plasmid.

Tambahan pula, analisis daripada RT-PCR menjelaskan transkripsi telah dihasilkan daripada lokus TA *MazEF*, ini menerangkan bahawa lokus ini telah berfungsi dalam isolat klinikal. Paras ekspresi bagi transkrip toksin telah meningkat apabila bakteria membiak di bawah beberapa keadaan yang stres. Di sampling itu, paras ATP sel telah menurun secara konsisten terhadap ekspresi toksin dan aktiviti *MazF*.

**Kata kunci:** sistem Toksin antitoksin, *MazEF*, *Staphylococcus aureus*, Asid Nukleotida Peptida.



## APPROVAL ACKNOWLEDGEMENTS

I would like to thank my supervisor, Prof. Zamberi Sekawi, for the patient guidance, encouragement, immense knowledge and advice he has provided throughout my time as his student. I have been extremely lucky to have a supervisor who cared so much about my work, and who responded to my questions and queries so promptly. I could not have imagined having a better advisor and mentor for my PhD study. I would also like to thank all the supervisory committee members, especially Prof. Liam Good for their encouragement, insightful comments, and hard questions who helped me in my supervisor's absence.

I would like thanks to my wife for her kindness and patients. She always supports me and be real friend.

I would like to thank my parents for everything they have done to nurture me and cultivate my interests. With the affection and inspiration from my parents, I feel it is a blessing to be their son. Since I was a child, I have seen my father as a role model. Therefore, first, I would like to dedicate my achievement to my beloved father, who inspired me to achieve my academic goals. I would like to thank my mother, who has provided me with endless love and support.

Last but not least, I thank those of my family, friends, and colleagues who always had faith in me and never let me give up on my dream, no matter how many obstacles came my way. I am blessed for having such strong pillars of support.

## DECLARATION

### Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: \_\_\_\_\_

Date: 25/05/2014

Name and Matric No.: Sobhan Ghafouryan, GS32164

## Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- Supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature:  
Name of  
Chairman of  
Supervisory  
Committee:

Signature:  
Name of  
Member of  
Supervisory  
Committee:

Signature:  
Name of  
Member of  
Supervisory  
Committee:

Signature:  
Name of  
Member of  
Supervisory  
Committee:

I certify that an Examination Committee has met on 3/02/2014 to conduct the final examination of Sobhan Ghafouryan on his Doctor of Philosophy thesis entitled “Toxin Antitoxin System as an Antimicrobial Target for Antibiotic Resistant *Staphylococcus aureus*” in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The Committee recommends that the student be awarded the Doctor of Philosophy degree.

Members of the Examination Committee were as follows:

**Name of Examiner 1, PhD**

Prof. Madya Dr. Zulita binit Zkaria  
Faculti perubatan Veterinar  
Universiti Putra Malaysia  
(Internal Examiner)

**Name of Examiner 2, PhD**

Prof. Dr. Son Rado  
Faculti Sains dan Teknologi Makanan  
Universiti Putra Malaysia  
(Internal Examiner)

**Name of External Examiner, PhD**

Prof. Madya Dr. Yinduo Ji  
Department of Veterinary Biomedical Sciences  
University of Minnesota  
United States  
(External Examiner)

---

**Seow Heng Fong, PhD**  
Professor and Deputy Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

**Zamberi bin Sekawi**

Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Vasanth Kumari Neela, PhD**

Associate Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

**Rukman Bin Awang Hamat**

Associate Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)

**Liam Good, PhD**

Professor  
Department of Pathology & Infectious Diseases/ Royal Veterinary College  
University of London  
(Member)

---

**BUJANG BIN KIM HUAT, PhD**  
Professor and Dean

Date:

## TABLE OF CONTENTS

|                                               |              |
|-----------------------------------------------|--------------|
| <b>ABSTRACT</b>                               | <b>Page</b>  |
| <b>ABSTRAK</b>                                | <b>ii</b>    |
| <b>APPROVAL ACKNOWLEDGEMENTS</b>              | <b>iv</b>    |
| <b>DECLARATION</b>                            | <b>vi</b>    |
| <b>LIST OF TABLES</b>                         | <b>vii</b>   |
| <b>LIST OF FIGURES</b>                        | <b>xv</b>    |
| <b>LIST OF ABBREVIATIONS</b>                  | <b>xvi</b>   |
|                                               | <b>xviii</b> |
| <b>CHAPTER</b>                                |              |
| <b>1 INTRODUCTION</b>                         | <b>1</b>     |
| 1.1 Introduction                              | 1            |
| 1.2 Statement of problem                      | 2            |
| 1.3 Statement of objectives                   | 3            |
| 1.4 Statement of hypothesis                   | 3            |
| <b>2 LITERATURE REVIEW</b>                    | <b>4</b>     |
| 2.1 <i>Staphylococcus aureus</i>              | 4            |
| 2.1.1 Antibiotic resistant <i>S. aureus</i>   | 4            |
| 2.1.2 Public health importance                | 4            |
| 2.1.3 Epidemiology                            | 5            |
| 2.1.4 Risk factors                            | 6            |
| 2.1.5 Treatment                               | 6            |
| 2.2 Toxin antitoxin (TA) system               | 7            |
| 2.2.1 Classification of TA system             | 8            |
| 2.2.1.1 Type I TA system                      | 8            |
| 2.2.1.2 Type II TA system                     | 9            |
| 2.2.1.3 Type III TA system                    | 10           |
| 2.2.1.4 Type IV TA system                     | 11           |
| 2.2.2 Functional analysis of TA systems       | 12           |
| 2.2.2.1 Genomic junk                          | 12           |
| 2.2.2.2 Toxin antitoxin system is selfish     | 12           |
| 2.2.2.3 Gene regulation                       | 13           |
| 2.2.2.4 Surveillance in bacteria              | 13           |
| 2.2.2.5 Persisters of the cells by TA systems | 13           |
| 2.2.2.6 Programmed cell death                 | 13           |

|                                                                                                                        |           |
|------------------------------------------------------------------------------------------------------------------------|-----------|
| 2.2.2.7 Antiphage activity                                                                                             | 13        |
| 2.2.2.8 Plasmid maintenance                                                                                            | 14        |
| 2.2.2.9 Biofilm formation                                                                                              | 14        |
| 2.2.3 Length of TA system                                                                                              | 14        |
| 2.2.4 Some important TA system                                                                                         | 15        |
| 2.3 Peptide Nucleic Acid (PNA)                                                                                         | 16        |
| <b>3 PREVALENCE AND LOCATION OF DIFFERENT TA SYSTEMS IN CLINICAL ISOLATES OF ANTIBIOTIC RESISTANT <i>S. AUREUS</i></b> | <b>19</b> |
| 3.1 Introduction                                                                                                       | 19        |
| 3.2 Material and Methods                                                                                               | 19        |
| 3.2.1 Bacterial isolates                                                                                               | 19        |
| 3.2.1.1 Characteristics of Milad hospital                                                                              | 20        |
| 3.2.1.2 Characteristics of Hospital Kuala Lumpur (HKL)                                                                 | 20        |
| 3.2.2 Sample collection                                                                                                | 20        |
| 3.2.2.1 Blood specimens                                                                                                | 20        |
| 3.2.2.2 Urine specimens                                                                                                | 21        |
| 3.2.2.3 Pus specimens                                                                                                  | 21        |
| 3.2.3 <i>S. aureus</i> identification                                                                                  | 21        |
| 3.2.3.1 Phenotypic identification of <i>S. Aureus</i>                                                                  | 21        |
| 3.2.3.2. Molecular identification of <i>S. Aureus</i>                                                                  | 21        |
| 3.2.4 Identification of MRSA                                                                                           | 22        |
| 3.2.4.1 McFarland turbidity standard                                                                                   | 22        |
| 3.2.4.2. <i>S. aureus</i> preparation of inoculums                                                                     | 22        |
| 3.2.4.3 Minimal Inhibitory Concentration (MIC) of oxacillin                                                            | 23        |
| 3.2.5 DNA extraction of <i>S. Aureus</i>                                                                               | 23        |
| 3.2.5.1 Spectrophotometric analysis of DNA                                                                             | 323       |
| 3.2.5.2 Evaluation of DNA quality                                                                                      | 24        |
| 3.2.6 Primer designing                                                                                                 | 24        |
| 3.2.7 Primer preparation                                                                                               | 25        |
| 3.2.8 Molecular identification of MRSA                                                                                 | 25        |
| 3.2.9 Determination of vancomycin resistant <i>S. Aureus</i>                                                           | 25        |
| 3.2.10 Antibiotic susceptibility of MRSA and MSSA strains                                                              | 25        |
| 3.2.10.1 Inoculation procedures                                                                                        | 26        |
| 3.2.10.2 Antimicrobial disks                                                                                           | 26        |
| 3.2.11 Plasmid extraction                                                                                              | 27        |
| 3.2.12 Evaluation of toxin-antitoxin systems                                                                           | 27        |
| 3.2.12.1 Purification of TA genes from agarose gel                                                                     | 27        |
| 3.2.13 Sequence analysis                                                                                               | 28        |
| 3.2.14 Plasmid purification from agarose gel                                                                           | 28        |
| 3.2.15 Plasmid transformation                                                                                          | 29        |
| 3.2.15.1 Electrocompetent cells preparation                                                                            | 29        |
| 3.2.15.2 Electroporation procedures                                                                                    | 29        |
| 3.2.16 Statistical analysis                                                                                            | 29        |
| 3.3 Results and Discussion                                                                                             | 30        |

|          |                                                                                                                      |           |
|----------|----------------------------------------------------------------------------------------------------------------------|-----------|
| 3.3.1    | <i>S. aureus</i> identification                                                                                      | 30        |
| 3.3.2    | MRSA and MSSA identification                                                                                         | 31        |
| 3.3.3    | Prevalence of <i>MazEF</i> , <i>HigBA</i> , <i>RelBE</i> and <i>Axe-Txe</i> TA genes among MRSA and MSSA.            | 34        |
| 3.3.3    | Transformation of <i>MazEF</i> TA system to <i>S. aureus</i> RN4220                                                  | 41        |
| 3.4      | Conclusion                                                                                                           | 43        |
| <b>4</b> | <b>EVALUATION FUNCTIONALITY OF MAZEF TA SYSTEM IN CLINICAL ISOLATES OF ANTIBIOTIC RESISTANT <i>S.AUREUS</i></b>      | <b>44</b> |
| 4.1      | Introduction                                                                                                         | 44        |
| 4.2      | Material and Methods                                                                                                 | 44        |
| 4.2.1    | Plasmid stability                                                                                                    | 44        |
| 4.2.2    | Reverse Transcriptase PCR (RT-PCR)                                                                                   | 45        |
| 4.2.2.1  | RNA extraction                                                                                                       | 45        |
| 4.2.2.2  | SCRIPT cDNA synthesis                                                                                                | 45        |
| 4.2.3    | Stress induction                                                                                                     | 46        |
| 4.2.4    | Turbidity assay by McFarland scale                                                                                   | 46        |
| 4.2.5    | ATpase activity and cell viability                                                                                   | 46        |
| 4.2.5.1  | ATP standard curve                                                                                                   | 47        |
| 4.2.6    | Real-Time quantitative PCR (RT-qPCR)                                                                                 | 47        |
| 4.2.6.1  | Standard curve for RT-qPCR                                                                                           | 49        |
| 4.2.6.2  | Prevention of RT-qPCR contamination                                                                                  | 50        |
| 4.2.6.3  | RT-qPCR reagent preparation                                                                                          | 51        |
| 4.2.7    | Statistical analysis                                                                                                 | 51        |
| 4.3      | Results and Discussion                                                                                               | 52        |
| 4.3.1    | <i>MazEF</i> TA loci as a responsible for plasmid maintenance in <i>S. aureus</i> containing <i>MazEF</i> TA system. | 52        |
| 4.3.2    | <i>MazEF</i> TA loci are expressed in antibiotic resistant <i>S. aureus</i> .                                        | 52        |
| 4.3.3    | Stress induction                                                                                                     | 53        |
| 4.3.4    | Functionality of the <i>MazEF</i> TA loci based on an evaluation of the quantity of toxin and antitoxin.             | 54        |
| 4.3.5    | ATP-based evaluation of the decrease in viable cells                                                                 | 56        |
| 4.3.5    | Effect of stress on concentration (CFU /ml) of <i>S. aureus</i> containing <i>MazEF</i> TA loci                      | 58        |
| 4.4      | Conclusion                                                                                                           | 60        |
| <b>5</b> | <b>EVALUATION OF MAZF TOXIN AGAINST ANTIBIOTIC RESISTANT <i>S. AUREUS</i></b>                                        | <b>61</b> |
| 5.1      | Introduction                                                                                                         | 61        |
| 5.2      | Material and Method                                                                                                  | 62        |
| 5.2.1    | PNA designing                                                                                                        | 62        |
| 5.2.2    | Preparation of PNA                                                                                                   | 62        |
| 5.2.3    | Antisense PNA therapy of <i>S. aureus</i> containing <i>MazEF</i> TA loci plasmid                                    | 62        |

|                                        |            |
|----------------------------------------|------------|
| 5.2.4 Statistical analysis             | 63         |
| 5.3 Results and Discussion             | 63         |
| 5.4 Conclusion                         | 65         |
| <b>6 CONCLUSION AND RECOMMENDATION</b> | <b>66</b>  |
| <b>REFERENCES</b>                      | <b>67</b>  |
| <b>APPENDICES</b>                      | <b>78</b>  |
| <b>BIO DATA OF STUDENT</b>             | <b>140</b> |
| <b>LIST OF PUBLICATION</b>             | <b>141</b> |



## LIST OF TABLES

| Table                                                                                               | Page |
|-----------------------------------------------------------------------------------------------------|------|
| 2.1 Examples of some common TA systems and their toxin activity                                     | 16   |
| 2.2 Comparison between PNA and DNA                                                                  | 17   |
| 3.1 <i>S. aureus</i> and MRSA collected from different infections in Milad Hospital and HKL         | 20   |
| 3.2 Characteristics of different primers used in the current study                                  | 24   |
| 3.3 Interpretation of antibiotic susceptibility testing by disk diffusion as M100-S22 CLSI protocol | 26   |
| 3.4 Antibiotic resistance pattern among MRSA and MSSA isolates in Milad hospital.                   | 33   |
| 3.5 Antibiotic resistance pattern among MRSA isolates in HKL.                                       | 34   |
| 3.6 Prevalence of TA loci among <i>S. aureus</i> isolated from Milad hospital.                      | 35   |
| 3.7 Prevalence of TA loci among MRSA isolates in HKL.                                               | 36   |
| 4.1 Primers and probes sequences in RT-qPCR                                                         | 48   |
| 4.2 RT-qPCR master mix preparation                                                                  | 51   |

## LIST OF FIGURES

| Figure |                                                                                                                                 | Page |
|--------|---------------------------------------------------------------------------------------------------------------------------------|------|
| 2.1    | Worldwide prevalence of MRSA                                                                                                    | 6    |
| 2.2    | Vertical and horizontal gene transfer of TA plasmid with in bacteria.                                                           | 7    |
| 2.3    | Type I TA system (hok/ sok); RNaseIII causes degradation of toxins                                                              | 9    |
| 2.4    | Neutralization of toxin by antitoxin and degradation of antitoxin by protease                                                   | 10   |
| 2.5    | Type III TA system                                                                                                              | 11   |
| 2.6    | Type IV TA system where antitoxin cleaved the mRNA toxin                                                                        | 12   |
| 2.7    | Location and length of Toxin-antitoxin system                                                                                   | 14   |
| 2.8    | Structure of PNA                                                                                                                | 17   |
| 3.1    | PCR results of <i>nuc</i> gene                                                                                                  | 30   |
| 3.2    | <i>MecA</i> gene identification in oxacillin resistant <i>S. aureus</i>                                                         | 31   |
| 3.3    | <i>vanA</i> gene in vancomycin resistant <i>S. aureus</i>                                                                       | 32   |
| 3.4    | Antibiotic resistance pattern among MRSA and MSSA isolates in Milad hospital                                                    | 32   |
| 3.5    | Antibiotic resistance pattern among MRSA isolates in HKL                                                                        | 33   |
| 3.6    | Prevalence of TA loci among <i>S. aureus</i> isolated from Milad hospital                                                       | 35   |
| 3.7    | Prevalence of TA loci among MRSA isolates in HKL                                                                                | 36   |
| 3.8    | PCR results of <i>MazE</i> and <i>MazF</i> TA loci                                                                              | 37   |
| 3.9    | PCR results of <i>Axt</i> and <i>Txe</i> TA loci                                                                                | 38   |
| 3.10   | PCR results of <i>RelB</i> and <i>RelE</i> TA loci                                                                              | 39   |
| 3.11   | PCR results of <i>HigB</i> and <i>HigA</i> TA loci                                                                              | 39   |
| 3.12   | Plasmid profiles of different <i>S. aureus</i> strains                                                                          | 42   |
| 3.13   | <i>S. aureus</i> RN4220 containing <i>MazEF</i> TA loci plasmid after transformation                                            | 43   |
| 4.1    | Calibration curve of McFarland scale                                                                                            | 46   |
| 4.2    | Calibration curve of ATP scale                                                                                                  | 47   |
| 4.3    | RT-qPCR analysis of <i>MazEF</i> TA system under normal and stress conditions                                                   | 55   |
| 4.4    | Luciferase reaction for determination of quantity of ATP                                                                        | 56   |
| 4.5    | Effect of stress on ATPase activity of <i>S. aureus</i> containing plasmid <i>MazEF</i> TA system                               | 57   |
| 4.6    | Decrease of ATP released by <i>S. aureus</i> under stress conditions on <i>S. aureus</i> harbored <i>MazEF</i> TA system during | 57   |

|     |                                                                                                                              |    |
|-----|------------------------------------------------------------------------------------------------------------------------------|----|
|     | each hour up to 12 hours and finally 24 hours                                                                                |    |
| 4.7 | Decrease of turbidity of <i>S. aureus</i> containing <i>MazEF</i> TA loci during 12 hours and finally 24 hours               | 59 |
| 4.8 | Effect of stress on <i>S. aureus</i> harboring <i>MazEF</i> TA loci during 12 hours and finally 24 hours                     | 60 |
| 5.1 | Effect of antiMaz-PNA against <i>S. aureus</i> containing <i>MazEF</i> TA system plasmid and without plasmid during 24 hours | 64 |
| 5.2 | Treated <i>S. aureus</i> RN4220 containing <i>MazEF</i> plasmid with antiMazE-PNA after 24 hours                             | 65 |



## LIST OF ABBREVIATION

|           |                                                    |
|-----------|----------------------------------------------------|
| TA system | Toxin antitoxin system                             |
| DNA       | Deoxyribonucleic acid                              |
| MRSA      | Methicillin Resistant <i>Staphylococcus aureus</i> |
| VRE       | Vancomycin Resistant Enterococcus                  |
| MSSA      | Methicillin Sensitive <i>Staphylococcus aureus</i> |
| RNA       | Ribonucleic acid                                   |
| PNA       | Peptide Nucleotide Acid                            |
| PMO       | Phosphorodiamidate Morpholino Oligomer             |
| LNA       | Locked Nucleic Acid                                |
| VRSA      | Vancomycin Resistant <i>Staphylococcus aureus</i>  |
| PSK       | Post Segregation Killing                           |
| PCD       | program cell's death                               |
| HKL       | Hospital Kuala Lumpur                              |
| MIC       | Minimal Inhibitory Concentration                   |
| PCR       | Polymerase Chain Reaction                          |
| RT-PCR    | Reverse Transcriptase PCR                          |
| RT-qPCR   | Real-Time quantitative PCR                         |
| ATP       | Adenosine Tri Phosphate                            |
| CTT       | Catalase Tube Test                                 |
| MSA       | Monnitrol Salt Agar                                |

## CHAPTER 1

### INTRODUCTION

#### 1.1 Introduction

The decade of the 1940s witnessed the introduction of penicillin, the first antimicrobial agent that was effective against *Staphylococcus aureus* (Kirby, 1944). Subsequently, resistance to penicillin was observed (Demerec, 1945) and during the two decades following the 1940s, penicillin resistant *S. aureus* became a worldwide concern (Rountree *et al.*, 1954). In 1959, methicillin was used for treatment of infections arising from penicillin resistant *S. aureus*. However, in 1961, the first Methicillin Resistant *Staphylococcus aureus* (MRSA) was reported (Jevons, 1961). Toxin-antitoxin (TA) systems, which were first described in the mid 1980s, are regulatory loci that encode a toxin and its corresponding antitoxin. The toxin and antitoxin may be an RNA or protein, but in all TA systems reported to date, the antitoxin is unstable, and the toxin is stable. TA loci appear to be more common in pathogenic bacteria, but many plasmids contain TA loci. One role of TA loci is to stabilize plasmids within cells, but they also play a role in stress resistance (Aizenman *et al.*, 1996). Plasmid stability is conferred by TA elements; at the time of cell division, all daughter cells will inherit stable toxin molecules or toxin-encoding mRNA, but only those cells that inherit plasmid DNA will be able to replenish sufficient antitoxin to survive. This process is termed 'post-segregational killing' (PSK) (Ogura & Hiraga, 1983; Faridani *et al.*, 2006). By this way, the bacteria that contain the TA loci on plasmid (commonly these plasmids also harbored the antibiotic resistant genes) will survive and the bacteria without plasmid containing TA loci and antibiotic resistant genes will be killed. Antisense therapy, which is sequence dependent, silences a specific gene. The antisense components are analogs of mRNA; therefore, this technology is involved in the inhibition of gene expression. Many techniques are available for antisense therapy that use different RNA analogs, such as phosphorodiamidate morpholino oligomers (PMOs), locked nucleic acids (LNAs) and peptide nucleic acids (PNA). Among these, the properties of PNAs make it particularly appropriate for antisense therapy in bacteria. This technique is applied for molecular bioengineering, therapeutic methods and antibiotics (Lee & Roth, 2003; Janson & Daringm 2006; Rasmussen *et al.*, 2007). The structure of PNAs is similar to that of DNA or RNA, except that the nucleobases are changed to a pseudopeptide (Nielsen *et al.*, 1991) following the Watson and Crick base-pairing rule; however, PNAs can bind DNA and RNA (Jensen *et al.*, 1997).

## 1.2 Statement of problem

Resistance to antibiotics develops through mutations of target sites or the acquisition of antibiotic resistant genes from other pathogens. To date, multiple drug resistance is the biggest challenge in the management of infectious diseases. While researches on development of new antibiotics are rapidly progressing, identification of new drug targets in microbes are also very important for effective infection control. The dissemination of antibiotic-resistance genes among nosocomial pathogens such as streptococci, staphylococci and *Enterobacteriaceae* has led to many cases of treatment failure. MRSA and vancomycin resistant *Staphylococcus aureus* (VRSA) are now global medical challenges. A global increase in MRSA worldwide and an increase in VRSA in Iran, the United States and India (Aligholiet *al.*, 2008; CDC, 2002; CDC, 2004; Perichon & Courvalin, 2009) have been reported. The identification of new bacterial drug targets is an important component in the effort to develop new drugs (Drews, 1996). Toxin antitoxin system could be a potent target for antibiotic therapy. In theory, the activation of a toxin or inhibition of an antitoxin is an attractive strategy for antimicrobial therapy (DeNap & Hergenrother, 2005; Engelberg-Kulka *et al.*, 2004). Amitai and colleagues demonstrated that 5% of bacterial cells were viable and 95% were killed after toxin activation because the increased toxin could not be neutralized by the antitoxin. However, when co-expressing *mazE* (antitoxin) and neutralizing *mazF* (toxin), 85% of the cells were viable because the toxin was neutralized and inhibited by the antitoxin (Amitai *et al.*, 2004). Hence, artificial disruption of antitoxin can lead to bacterial cell killing. However, the most important step for potency of TA system, as an antibacterial target, is to identify a TA system that is prevalent in all resistant clinical strains and determine its functionality. While the analysis of TA system can be instructive, until now, there is no information on the prevalence and identity of TA systems in a large panel of *S. aureus* clinical isolates. Therefore, it is necessary to study a TA system that is prevalent and transcribed in all clinical antibiotic resistant *S. aureus* and evaluate this target for antimicrobial therapy.

## 1.3 Statement of objectives

### 1.3.1 General objective

To evaluate the antitoxin (*MazE*) as an attractive antimicrobial target for the eradication of antibiotic resistant *S. aureus*.

### 1.3.2 Specific objectives

1. To determine the prevalence of different TA systems, their location on plasmid or chromosome and the dominant TA system in clinical isolates of antibiotic resistant *S. aureus*.

2. To evaluate functionality of TA system in all clinical isolates of antibiotic resistant *S. aureus*.
3. To evaluate effect of *MazF* toxin against antibiotic resistant *S. aureus*.

#### 1.4 Statement of hypothesis

Based upon these data, it hypothesized that the identification of a dominant TA system in antibiotic resistant *S. aureus* will provide a novel antibacterial target against *S. aureus* infections.



## REFERENCES

- Aguirre-Ramirez, M., J. Ramirez-Santos, L. Van Melderren, and M. C. Gomez-Eichelmann. "Expression of the F Plasmid Ccd Toxin-Antitoxin System in Escherichia Coli Cells under Nutritional Stress." *Can J Microbiol* 52, no. 1 (2006): 24-30.
- Aires de Sousa, M., T. Conceicao, C. Simas, and H. de Lencastre. "Comparison of Genetic Backgrounds of Methicillin-Resistant and -Susceptible Staphylococcus Aureus Isolates from Portuguese Hospitals and the Community." *J Clin Microbiol* 43, no. 10 (2005): 5150-7.
- Aizenman, E., H. Engelberg-Kulka, and G. Glaser. "An *Escherichia Coli* Chromosomal "Addiction Module" Regulated by Guanosine [Corrected] 3',5'-Bispyrophosphate: A Model for Programmed Bacterial Cell Death." *Proc Natl Acad Sci U S A* 93, no. 12 (1996): 6059-63.
- Alekshun, M. N., and S. B. Levy. "Molecular mechanisms of antibacterial multidrug resistance." *Cell*, 6 (2007): 1037-1050.
- Aligholi, M., M. Emaneini, F. Jabalameli, S. Shahsavan, H. Dabiri, and H. Sedaght. "Emergence of High-Level Vancomycin-Resistant Staphylococcus Aureus in the Imam Khomeini Hospital in Tehran." *Med Princ Pract* 17, no. 5 (2008): 432-4.
- Amitai, S., Y. Yassin, and H. Engelberg-Kulka. "Mazf-Mediated Cell Death in Escherichia Coli: A Point of No Return." *J Bacteriol* 186, no. 24 (2004): 8295-300.
- Anderson, K. L., C. Robert, T. Disc, and V. Vonstein V. "Characterization of Staphylococcus aureus heat shock, cold shock, stringent, and SOS responses and their effect on log phase Mrna turnover." *J Bacteriol* 188 (2006): 6739-6756.
- Bahassi, E. M., M. A. Salmon, L. Van Melderren, P. Bernard, and M. Couturier. "F Plasmid Ccdb Killer Protein: Ccdb Gene Mutants Coding for Non-Cytotoxic Proteins Which Retain Their Regulatory Functions." *Mol Microbiol* 15, no. 6 (1995): 1031-7.
- Bauer, A. W., W. M. Kirby, J. C. Sherris, and M. Turck. "Antibiotic Susceptibility Testing by a Standardized Single Disk Method." *Am J Clin Pathol* 45, no. 4 (1966): 493-6.
- Bernard, P., and M. Couturier. "Cell Killing by the F Plasmid Ccdb Protein Involves Poisoning of DNA-Topoisomerase Ii Complexes." *J Mol Biol* 226, no. 3 (1992): 735-45.
- Blower, T.R., G. C. P. Salmond, and B. F. Luis. "Balancing at survival's edge: the structure and adaptive benefits of prokaryotic toxin-antitoxin partners." *Current Opinion Structural Biol.* 21 (2011): 109-118.
- Blower, T. R., X. Y. Pei, F. L. Short, P. C. Fineran, D. P. Humphreys, B. F. Luisi, and G. P. Salmond. "A Processed Noncoding Rna Regulates an

- Altruistic Bacterial Antiviral System." *Nat Struct Mol Biol* 18, no. 2 (2011): 185-90.
- Borer, A., J. Gilad, P. Yagupsky, N. Peled, N. Porat, R. Trefler, H. Shprecher-Levy, and K. Riesenberger, M. Shipman, and F. Schlaeffer. "Community-Acquired Methicillin-Resistant Staphylococcus Aureus in Institutionalized Adults with Developmental Disabilities." *Emerg Infect Dis* 8, no. 9 (2002): 966-70.
- Brantl, S. Antisense-RNA regulation and RNA interference. *Biochim Biophys Acta* 1575, (2002): 15-25.
- Buts, L., J. Lah, M. H. Dao-Thi, L. Wyns, and R. Loris. "Toxin-Antitoxin Modules as Bacterial Metabolic Stress Managers." *Trends Biochem Sci* 30, no. 12 (2005): 672-9.
- Caprara, M. G., and T.W. Nilsen. "RNA: versatility in form and function." *Nat Struct Biol* 7, (2000): 831-3.
- Centers for Disease Control and Prevention. "Definition of MRSA". (2010).
- Centers for Disease Control and Prevention. "Four Pediatric Deaths from Community-Acquired Methicillin-Resistant Staphylococcus Aureus -- Minnesota and North Dakota, 1997-1999." *MMWR Morb Mortal Wkly Rep* 48, no. 32 (1999): 707-10.
- Centers for Disease Control and Prevention. "Vancomycin-Resistant Staphylococcus Aureus--Pennsylvania, 2002." *MMWR Morb Mortal Wkly Rep* 51, no. 40 (2002): 902.
- Centers for Disease Control and Prevention. "Vancomycin-Resistant Staphylococcus Aureus--New York, 2004." *MMWR Morb Mortal Wkly Rep* 53, no. 15 (2004): 322-3.
- Chan, W. T., C. Nieto, J. A. Harikrishna, S. K. Khoo, R. Y. Othman, M. Espinosa, and C. C. Yeo. "Genetic Regulation of the Yefm-YoeB Toxin-Antitoxin Locus of Streptococcus Pneumoniae." *J Bacteriol* 193, no. 18 (2011): 4612-25.
- Cherny, I., M. Overgaard, J. Borch, Y. Bram, K. Gerdes, and E. Gazit. "Structural and Thermodynamic Characterization of the Escherichia Coli Relbe Toxin-Antitoxin System: Indication for a Functional Role of Differential Stability." *Biochemistry* 46, no. 43 (2007): 12152-63.
- Christensen-Dalsgaard, M., M. Overgaard, K. S. Winther, and K. Gerdes. "Rna Decay by Messenger Rna Interferases." *Methods Enzymol* 447 (2008): 521-35.
- Christensen, S. K., and K. Gerdes. "RelE Toxins from Bacteria and Archaea Cleave Mrnas on Translating Ribosomes, Which Are Rescued by Tmrna." *Mol Microbiol* 48, no. 5 (2003): 1389-400.
- Christensen, S. K., M. Mikkelsen, K. Pedersen, and K. Gerdes. "RelE, a Global Inhibitor of Translation, Is Activated During Nutritional Stress." *Proc Natl Acad Sci U S A* 98, no. 25 (2001): 14328-33.

- Christensen, S. K., K. Pedersen, F. G. Hansen, and K. Gerdes. "Toxin-Antitoxin Loci as Stress-Response-Elements: ChpK/MazF and ChpK Cleave Translated RNAs and Are Counteracted by Tmrna." *J Mol Biol* 332, no. 4 (2003): 809-19.
- Clinical and Laboratory Standards Institute (CLSI). "Principles and Procedures for Blood Cultures; Approved Guideline". CLSI document M47-A. Wayne, PA: Clinical and Laboratory Standards Institute (2007).
- Clinical and Laboratory Standards Institute (CLSI). "Performance Standards for Antimicrobial Susceptibility Testing." CLSI document document M100-s22. Wayne, PA: Clinical and Laboratory Standards Institute (2012).
- Cooper, T. F., and J. A. Heinemann. "Postsegregational Killing Does Not Increase Plasmid Stability but Acts to Mediate the Exclusion of Competing Plasmids." *Proc Natl Acad Sci U S A* 97, no. 23 (2000): 12643-8.
- Cosgrove, S. E., Y. Qi, K. S. Kaye, S. Harbarth, A. W. Karchmer, and Y. Carmeli. "The Impact of Methicillin Resistance in Staphylococcus Aureus Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges." *Infect Control Hosp Epidemiol* 26, no. 2 (2005): 166-74.
- Crowcroft, N. S., and M. Catchpole. "Mortality from Methicillin Resistant Staphylococcus Aureus in England and Wales: Analysis of Death Certificates." *BMJ* 325, no. 7377 (2002): 1390-1.
- Delaney, J. A., V. Schneider-Lindner, P. Brassard, and S. Suissa. "Mortality after Infection with Methicillin-Resistant Staphylococcus Aureus (Mrsa) Diagnosed in the Community." *BMC Med* 6 (2008): 2.
- Demerec, M. "Production of Staphylococcus Strains Resistant to Various Concentrations of Penicillin." *Proc Natl Acad Sci U S A* 31, no. 1 (1945): 16-24.
- Demidov, V. V., V. N. Potaman, M. D. Frank-Kamenetskii, M. Egholm, O. Buchard, S. H. Sonnichsen, and P. E. Nielsen. "Stability of Peptide Nucleic Acids in Human Serum and Cellular Extracts." *Biochem Pharmacol* 48, no. 6 (1994): 1310-3.
- DeNap, J. C., and P. J. Hergenrother. "Bacterial Death Comes Full Circle: Targeting Plasmid Replication in Drug-Resistant Bacteria." *Org Biomol Chem* 3, no. 6 (2005): 959-66.
- Diekema, D. J., M. A. Pfaller, F. J. Schmitz, J. Smayevsky, J. Bell, R. N. Jones, and M. Beach. "Survey of Infections Due to Staphylococcus Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999." *Clin Infect Dis* 32 Suppl 2 (2001): S114-32.
- Dryselius, R., S.K. Aswasti, G.K. Rajarao, P.E. Nielsen, and L. Good. "The translation start codon region is sensitive to antisense PNA inhibition in Escherichia coli." *Oligonucleotides* 13, (2003):427-433.

- Durand, S., N. Jahn, C. Condon, and S. Brantl. "Type I Toxin-Antitoxin Systems in *Bacillus Subtilis*." *RNA Biol* 9, no. 12 (2012): 1491-7.
- Engelberg-Kulka, H., R. Hazan, and S. Amitai. "Mazef: A Chromosomal Toxin-Antitoxin Module That Triggers Programmed Cell Death in Bacteria." *J Cell Sci* 118, no. Pt 19 (2005): 4327-32.
- Engelberg-Kulka, H., B. Sat, M. Reches, S. Amitai, and R. Hazan. "Bacterial Programmed Cell Death Systems as Targets for Antibiotics." *Trends Microbiol* 12, no. 2 (2004): 66-71.
- Faridani, O. R., A. Nikraves, D. P. Pandey, K. Gerdes, and L. Good. "Competitive Inhibition of Natural Antisense Tok-Rna Interactions Activates Hok-Mediated Cell Killing in *Escherichia Coli*." *Nucleic Acids Res* 34, no. 20 (2006): 5915-22.
- Fineran, P. C., T. R. Blower, I. J. Foulds, D. P. Humphreys, K. S. Lilley, and G. P. Salmond. "The Phage Abortive Infection System, Toxin, Functions as a Protein-Rna Toxin-Antitoxin Pair." *Proc Natl Acad Sci U S A* 106, no. 3 (2009): 894-9.
- Fozo, E. M. "New Type I Toxin-Antitoxin Families from "Wild" and Laboratory Strains of *E. Coli*: Ibs-Sib, Shob-Ohsc and Zor-Orz." *RNA Biol* 9, no. 12 (2012): 1504-12.
- Fozo, E. M., M. R. Hemm, and G. Storz. "Small Toxic Proteins and the Antisense Rnas That Repress Them." *Microbiol Mol Biol Rev* 72, no. 4 (2008): 579-89, Table of Contents.
- Fozo, E. M., K. S. Makarova, S. A. Shabalina, N. Yutin, E. V. Koonin, and G. Storz. "Abundance of Type I Toxin-Antitoxin Systems in Bacteria: Searches for New Candidates and Discovery of Novel Families." *Nucleic Acids Res* 38, no. 11 (2010): 3743-59.
- Frees, D., A. Chastanet, S. Qazi, K. Sorensen, P. Hill, T. Msadek, and H. Ingmer. "Clp ATPases Are Required for Stress Tolerance, Intracellular Replication and Biofilm Formation in *Staphylococcus Aureus*." *Mol Microbiol* 54, no. 5 (2004): 1445-62.
- Gaibani, P., G. Rossini, S. Ambretti, F. Gelsomino, A. M. Pierro, S. Varani, M. Paolucci, M. P. Landini, and V. Sambri. "Blood Culture Systems: Rapid Detection--How and Why?" *Int J Antimicrob Agents* 34 Suppl 4 (2009): S13-5.
- Gerdes, K. "Toxin-Antitoxin Modules May Regulate Synthesis of Macromolecules During Nutritional Stress." *J Bacteriol* 182, no. 3 (2000): 561-72.
- Goh, S., J. M. Boberek, N. Nakashima, J. Stach, and L. Good. "Concurrent Growth Rate and Transcript Analyses Reveal Essential Gene Stringency in *Escherichia Coli*." *PLoS One* 4, no. 6 (2009): e6061.
- Gonzalez Barrios, A. F., R. Zuo, Y. Hashimoto, L. Yang, W. E. Bentley, and T. K. Wood. "Autoinducer 2 Controls Biofilm Formation in *Escherichia Coli* through a Novel Motility Quorum-Sensing Regulator (Mqsr, B3022)." *J Bacteriol* 188, no. 1 (2006): 305-16.

- Good, L., S. K. Awasthi, R. Dryselius, O. Larsson, and P. E. Nielsen. "Bactericidal Antisense Effects of Peptide-Pna Conjugates." *Nat Biotechnol* 19, no. 4 (2001): 360-4.
- Good, L., R. Dryselius, and P. E. Nielsen. "Antisense effects in Escherichia coli." In: Nielsen PE (ed) *Peptide nucleic acids*, (2004) Protocols.
- Good, L., and P. E. Nielsen. "Antisense Inhibition of Gene Expression in Bacteria by Pna Targeted to Mrna." *Nat Biotechnol* 16, no. 4 (1998): 355-8.
- Good, L., R. Sandberg, O. Larsson, P. E. Nielsen, and C. Wahlestedt. "Antisense Pna Effects in Escherichia Coli Are Limited by the Outer-Membrane Lps Layer." *Microbiology* 146 ( Pt 10) (2000): 2665-70.
- Gotfredsen, M., and K. Gerdes. "The Escherichia Coli Relbe Genes Belong to a New Toxin-Antitoxin Gene Family." *Mol Microbiol* 29, no. 4 (1998): 1065-76.
- Grady, R., and F. Hayes. "Axe-Txe, a Broad-Spectrum Proteic Toxin-Antitoxin System Specified by a Multidrug-Resistant, Clinical Isolate of Enterococcus Faecium." *Mol Microbiol* 47, no. 5 (2003): 1419-32.
- Gross, M., I. Marianovsky, and G. Glaser. "Mazg -- a Regulator of Programmed Cell Death in Escherichia Coli." *Mol Microbiol* 59, no. 2 (2006): 590-601.
- Grubb, W.B. "Genetics of Mrsa." *Reviews in Medical Microbiology* 9 (1998): 153-62.
- Grundmann, H., M. Aires-de-Sousa, J. Boyce, and E. Tiemersma. "Emergence and Resurgence of Methicillin-Resistant Staphylococcus Aureus as a Public Health Threat." *Lancet* 368 (2006): 874-85.
- Grundmann, H., D.M. Aanensen, C.C. van den Wijngaard, B.G. Spratt, D. Harmsen, and A.W. Friedrich. "Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis." *PLoS Med* (2010);7:e1000215.
- Hang, Y., J. Zhang, K.P. Hoeflich, M. Ikura, G. Qing, and M. Inouye. "MazF cleaves cellular mRNAs specifically at ACA to block protein synthesis in Escherichia coli." *Mol. Cell* 12 (2003): 913-23.
- Harrison, J. J., W. D. Wade, S. Akierman, C. Vacchi-Suzzi, C. A. Stremick, R. J. Turner, and H. Ceri. "The Chromosomal Toxin Gene Yafq Is a Determinant of Multidrug Tolerance for Escherichia Coli Growing in a Biofilm." *Antimicrob Agents Chemother* 53, no. 6 (2009): 2253-8.
- Hattori, N., T. Sakakibara, N. Kajiya, T. Igarashi, M. Maeda, and S. Murakami. "Enhanced Microbial Biomass Assay Using Mutant Luciferase Resistant to Benzalkonium Chloride." *Anal Biochem* 319, no. 2 (2003): 287-95.
- Hayes, F. "Toxins-Antitoxins: Plasmid Maintenance, Programmed Cell Death, and Cell Cycle Arrest." *Science* 301, no. 5639 (2003): 1496-9.

- Hazan, R., and H. Engelberg-Kulka. "Escherichia Coli Mazef-Mediated Cell Death as a Defense Mechanism That Inhibits the Spread of Phage P1." *Mol Genet Genomics* 272, no. 2 (2004): 227-34.
- Hazan, R., B. Sat, and H. Engelberg-Kulka. "Escherichia Coli Mazef-Mediated Cell Death Is Triggered by Various Stressful Conditions." *J Bacteriol* 186, no. 11 (2004): 3663-9.
- Janson, C.G., and M.J. During. "Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules." *Kluwer Academic/plenum publishers, New York* (2006).
- Jensen, K. K., H. Orum, P. E. Nielsen, and B. Norden. "Kinetics for Hybridization of Peptide Nucleic Acids (Pna) with DNA and Rna Studied with the Biacore Technique." *Biochemistry* 36, no. 16 (1997): 5072-7.
- Jevons, M. "'Celbenin' - Resistant Staphylococci." *BMJ* 1 (1961): 124-25.
- Johnson, A. P., A. Pearson, and G. Duckworth. "Surveillance and Epidemiology of Mrsa Bacteraemia in the Uk." *J Antimicrob Chemother* 56, no. 3 (2005): 455-62.
- Johnson, A. S., C. Touchie, D. J. Haldane, and K. R. Forward. "Four-Day Incubation for Detection of Bacteremia Using the Bactec 9240." *Diagn Microbiol Infect Dis* 38, no. 4 (2000): 195-9.
- Kawano, M. "Divergently Overlapping Cis-Encoded Antisense Rna Regulating Toxin-Antitoxin Systems from E. Coli: Hok/Sok, Ldr/Rdl, Syme/Symr." *RNA Biol* 9, no. 12 (2012): 1520-7.
- Kazakova, S. V., J. C. Hageman, M. Matava, A. Srinivasan, L. Phelan, B. Garfinkel, T. Boo, S. McAllister, J. Anderson, B. Jensen, D. Dodson, D. Lonsway, L. K. McDougal, M. Arduino, V. J. Fraser, G. Killgore, F. C. Tenover, S. Cody, and D. B. Jernigan. "A Clone of Methicillin-Resistant Staphylococcus Aureus among Professional Football Players." *N Engl J Med* 352, no. 5 (2005): 468-75.
- Khatib, R., K. Riederer, S. Saeed, L. B. Johnson, M. G. Fakih, M. Sharma, M. S. Tabriz, and A. Khosrovaneh. "Time to Positivity in Staphylococcus Aureus Bacteremia: Possible Correlation with the Source and Outcome of Infection." *Clin Infect Dis* 41, no. 5 (2005): 594-8.
- Kim, Y., X. Wang, Q. Ma, X. S. Zhang, and T. K. Wood. "Toxin-Antitoxin Systems in Escherichia Coli Influence Biofilm Formation through Yjgk (Taba) and Fimbriae." *J Bacteriol* 191, no. 4 (2009): 1258-67.
- Kirby, H. "Une Faute De Transcription, D'orthographe, Ou D'impression." *Science* 100, no. 2602 (1944): 425-7.
- Klevens, R. M., J. R. Edwards, F. C. Tenover, L. C. McDonald, T. Horan, and R. Gaynes. "Changes in the Epidemiology of Methicillin-Resistant Staphylococcus Aureus in Intensive Care Units in Us Hospitals, 1992-2003." *Clin Infect Dis* 42, no. 3 (2006): 389-91.
- Kolodkin-Gal, I., and H. Engelberg-Kulka. "Induction of Escherichia Coli Chromosomal Mazef by Stressful Conditions Causes an Irreversible Loss of Viability." *J Bacteriol* 188, no. 9 (2006): 3420-3.

- Knudsen, H., and P.E. Nielsen. "Antisense properties of duplex- and triplex-forming PNAs." *Nucl Acids Res* 24, (1996):494-500.
- Kurreck, J. "Antisense technologies: improvement through novel chemical modifications." *Eur J Biochem* 270, (2003):1628-1644.
- Lee, A., S. Mirrett, L. B. Reller, and M. P. Weinstein. "Detection of Bloodstream Infections in Adults: How Many Blood Cultures Are Needed?" *J Clin Microbiol* 45, no. 11 (2007): 3546-8.
- Lee, L. K., and C. M. Roth. "Antisense Technology in Molecular and Cellular Bioengineering." *Curr Opin Biotechnol* 14, no. 5 (2003): 505-11.
- Lewis, K. "Multidrug Tolerance of Biofilms and Persister Cells." *Curr Top Microbiol Immunol* 322 (2008): 107-31.
- Lipsky, B.A., Y.P. Tabak, R.S. Johannes, L. Vo, L. Hyde, and J.A. Weigelt. "Skin and Soft Tissue Infections in Hospitalised Patients with Diabetes: Culture Isolates and Risk Factors Associated with Mortality, Length of Stay and Cost." *Diabetologia* 53, no. 5 (2010): 914-23.
- Lowy, F. D. "Antimicrobial Resistance: The Example of Staphylococcus Aureus." *J Clin Invest* 111, no. 9 (2003): 1265-73.
- Maida, I., M. Fondi, M.c. Papaleo, E. Perrin, and R. Fani. "The Gene Flow between Plasmids and Chromosomes: Insights from Bioinformatics Analyses." *Open Applied Informatics Journal* 5 (2011): 62.
- Maisonneuve, E., L. J. Shakespeare, M. G. Jorgensen, and K. Gerdes. "Bacterial Persistence by Rna Endonucleases." *Proc Natl Acad Sci U S A* 108, no. 32 (2011): 13206-11.
- Malani, A., K. Trimble, V. Parekh, C. Chenoweth, S. Kaufman, and S. Saint. "Review of Clinical Trials of Skin Antiseptic Agents Used to Reduce Blood Culture Contamination." *Infect Control Hosp Epidemiol* 28, no. 7 (2007): 892-5.
- Mancini, N., S. Carletti, N. Ghidoli, P. Cichero, R. Burioni, and M. Clementi. "The Era of Molecular and Other Non-Culture-Based Methods in Diagnosis of Sepsis." *Clin Microbiol Rev* 23, no. 1 (2010): 235-51.
- Mansoor, M., and A.J. Melendez. "Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics." *Gene Regul Syst Bio* 2, (2008):275-295.
- Martin, S. S., and A. E. Senior. "Membrane Adenosine Triphosphatase Activities in Rat Pancreas." *Biochim Biophys Acta* 602, no. 2 (1980): 401-18.
- Masuda, Y., K. Miyakawa, Y. Nishimura, and E. Ohtsubo. "Chpa and Chpb, Escherichia Coli Chromosomal Homologs of the Pem Locus Responsible for Stable Maintenance of Plasmid R100." *J Bacteriol* 175, no. 21 (1993): 6850-6.
- McFarland, J. "The Nephelometer: An Instrument for Estimating the Number of Bacteria in Suspensions Used for Calculating the Opsonic Index and for Vaccines." *JAMA* 14 (1907): 1176-78.
- Mejia, C., J. Zurita, M. Guzman-Blanco. "Epidemiology and surveillance of methicillin-resistant Staphylococcus aureus in Latin America." *Braz J Infect Dis* 14 Suppl. 2 (2010):S79-86.

- Melderen , L.V., and M. Saavedra De Bast. "Bacterial Toxin-Antitoxin Systems: More Than Selfish Entities?" *PLoS Genetics* 5, no. 3 (2009): 1-6.
- Mizuno, T., M.Y. Chou, and M. Inouye. "A unique mechanism regulation gene expression: translation inhibition by a complementary RNA transcript (micRNA)." *Proc Natl Acad Sci U S A* 81, (1984): 1966-70.
- Mochizuki, A., K. Yahara, I. Kobayashi, and Y. Iwasa. "Genetic Addiction: Selfish Gene's Strategy for Symbiosis in the Genome." *Genetics* 172, no. 2 (2006): 1309-23.
- Mongkolrattanothai , K. , S. Boyle , M.D. Kahana , and R.S. Daum. "Severestaphylococcus Aureus Infections Caused by Clonally Related Community-Associated Methicillin-Susceptible and Methicillin-Resistant Isolates." *Clin. Infect. Dis.* 37, no. 8 (2003): 1050-8.
- Moritz, E. M., and P. J. Hergenrother. "Toxin-Antitoxin Systems Are Ubiquitous and Plasmid-Encoded in Vancomycin-Resistant Enterococci." *Proc Natl Acad Sci U S A* 104, no. 1 (2007): 311-6.
- Munoz-Gomez, A. J., S. Santos-Sierra, A. Berzal-Herranz, M. Lemonnier, and R. Diaz-Orejas. "Insights into the Specificity of Rna Cleavage by the Escherichia Coli Mazf Toxin." *FEBS Lett* 567, no. 2-3 (2004): 316-20.
- Murray, B. E., and R. C. Moellering, Jr. "Patterns and Mechanisms of Antibiotic Resistance." *Med Clin North Am* 62, no. 5 (1978): 899-923.
- Murray, P.R., E.J. Baron , J.H. Jorgensen , M.L. Landry , and M.A. Pfaller *Manual of Clinical Microbiology*. Edited by 9th ed: American Society for Microbiology, 2007.
- Nielsen, P. E., and M. Egholm. "An Introduction to Peptide Nucleic Acid." *Curr Issues Mol Biol* 1, no. 1-2 (1999): 89-104.
- Nielsen, P. E., M. Egholm, R. H. Berg, and O. Buchardt. "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide." *Science* 254, no. 5037 (1991): 1497-500.
- Nieto, C., I. Cherny, S. K. Khoo, M. G. de Lacoba, W. T. Chan, C. C. Yeo, E. Gazit, and M. Espinosa. "The Yefm-Yoeb Toxin-Antitoxin Systems of Escherichia Coli and Streptococcus Pneumoniae: Functional and Structural Correlation." *J Bacteriol* 189, no. 4 (2007): 1266-78.
- Nieto, C., E. Sadowy, A.G. De la Campa, W. Hryniewicz, and M. Espinosa. "The relBE2Spn toxin-antitoxin system of Streptococcus pneumoniae: role in antibiotic tolerance and functional conservation in clinical isolates." *PLoS ONE* no 5, (2010), e11289.
- Nikaido, H. "Prevention of Drug Access to Bacterial Targets: Permeability Barriers and Active Efflux." *Science* 264, no. 5157 (1994): 382-8.
- Ning, D., Y. Jiang, Z. Liu, and Q. Xu. "Characterization of a Chromosomal Type II Toxin-Antitoxin System MazE/MazF in the Cyanobacterium Anabaena Sp. Pcc 7120." *PLoS One* 8, no. 2 (2013): e56035.
- Ochman, H., and L. M. Davalos. "The Nature and Dynamics of Bacterial Genomes." *Science* 311, no. 5768 (2006): 1730-3.

- Ogata , K., H. Narimatsu , M. Suzuki , W. Higuchi , T. Yamamoto , and H. Taniguchi. "Commercially Distributed Meat as a Potential Vehicle for Community-Acquired Methicillin-Resistant Staphylococcus Aureus"." *Applied and environmental microbiology* 78, no. 8 (2012): 2797-802.
- Ogura , T., and S. Hiraga. " Mini-F Plasmid Genes That Couple Host Cell Division to Plasmid Proliferation." *Proc. Natl. Acad. Sci. U.S.A.* 80 (1983): 4784-88
- Pandey, D. P., and K. Gerdes. "Toxin-Antitoxin Loci Are Highly Abundant in Free-Living but Lost from Host-Associated Prokaryotes." *Nucleic Acids Res* 33, no. 3 (2005): 966-76.
- Pecota, D. C., and T. K. Wood. "Exclusion of T4 Phage by the Hok/Sok Killer Locus from Plasmid R1." *J Bacteriol* 178, no. 7 (1996): 2044-50.
- Pedersen, K., S. K. Christensen, and K. Gerdes. "Rapid Induction and Reversal of a Bacteriostatic Condition by Controlled Expression of Toxins and Antitoxins." *Mol Microbiol* 45, no. 2 (2002): 501-10.
- Perichon, B., and P. Courvalin. "Vana-Type Vancomycin-Resistant Staphylococcus Aureus." *Antimicrob Agents Chemother* 53, no. 11 (2009): 4580-7.
- Ramage, H. R., L. E. Connolly, and J. S. Cox. "Comprehensive Functional Analysis of Mycobacterium Tuberculosis Toxin-Antitoxin Systems: Implications for Pathogenesis, Stress Responses, and Evolution." *PLoS Genet* 5, no. 12 (2009): e1000767.
- Rasmussen , L., H. Sperling-Petersen , and K. Mortensen. "Hitting Bacteria at the Heart of the Central Dogma: Sequence-Specific Inhibition." *Microb Cell Fact* 6 (2007): 1-24.
- Ryan, K., C. G. Ray, N. Ahmad, W. L. Drew, and J. Plorde. *Sherris Medical Microbiology*, 5th Edition, 2010.
- Rohani, M. . "Antibiotic Resistance Patterns of Bacteria Isolated in Malaysian Hospitals." *Int. Med. J.* 6 (1999): 47- 51.
- Rountree, P. M., B. M. Freeman, and R. G. Barbour. "Nasal Carriage of Staphylococcus Aureus in the General Population and Its Relationship to Hospitalization and to Penicillin Therapy." *Med J Aust* 2, no. 12 (1954): 457-60.
- Sambrook , J.F., and D.W. Russel *Molecular Cloning: A Laboratory Manual*. Edited by 3ed. NEW York: Cold Spring Harbor Laboratory Press, 2001.
- Sat, B., R. Hazan, T. Fisher, H. Khaner, G. Glaser, and H. Engelberg-Kulka. "Programmed Cell Death in Escherichia Coli: Some Antibiotics Can Trigger Mazef Lethality." *J Bacteriol* 183, no. 6 (2001): 2041-5.
- Schaeffler, S., D. Jones, W. Perry, L. Ruvinskaya, T. Baradet, E. Mayr, and M. E. Wilson. "Emergence of Gentamicin- and Methicillin-Resistant Staphylococcus Aureus Strains in New York City Hospitals." *J Clin Microbiol* 13, no. 4 (1981): 754-9.
- Schmidt, O., V. J. Schuenemann, N. J. Hand, T. J. Silhavy, J. Martin, A. N. Lupas, and S. Djuranovic. "Prf and Yhav Encode a New Toxin-

- Antitoxin System in Escherichia Coli." *J Mol Biol* 372, no. 4 (2007): 894-905.
- Sevin, E. W., and F. Barloy-Hubler. "Rasta-Bacteria: A Web-Based Tool for Identifying Toxin-Antitoxin Loci in Prokaryotes." *Genome Biol* 8, no. 8 (2007): R155.
- Sletvold, H., P. J. Johnsen, G. S. Simonsen, B. Aasnaes, A. Sundsfjord, and K. M. Nielsen. "Comparative DNA Analysis of Two Vana Plasmids from Enterococcus Faecium Strains Isolated from Poultry and a Poultry Farmer in Norway." *Antimicrob Agents Chemother* 51, no. 2 (2007): 736-9.
- Song, J. H., P.R. Hsueh, D.R. Chung, K.S. Ko, C.L. Kang, and K.R. Peck. "Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries: an ANSORP study." *J Antimicrob Chemother* 66 (2011):1061-9.
- Stanley, P. E. "Extraction of Adenosine Triphosphate from Microbial and Somatic Cells." *Methods Enzymol* 133 (1986): 14-22.
- Stouggard, P., S. Molin, and K. Nordstrom. "RNAs invoved in copy number control and incompatibility of plasmid R1." *Proc Natl Acad Sci U S A* 78, (1981): 6008-12.
- Tacconelli , E., G. De Angelis , M.A. Cataldo , E. Pozzi , and R. Cauda. "Does Antibiotic Exposure Increase the Risk of Methicillin-Resistant Staphylococcus Aureus (Mrsa) Isolation? A Systematic Review and Meta-Analysis." *J Antimicrob Chemother* 61, no. 1 (2008): 26-38.
- Tian, Q. B., M. Ohnishi, A. Tabuchi, and Y. Terawaki. "A New Plasmid-Encoded Proteic Killer Gene System: Cloning, Sequencing, and Analyzing Hig Locus of Plasmid Rts1." *Biochem Biophys Res Commun* 220, no. 2 (1996): 280-4.
- Tomizava, J., T. Itoh, G. Selzer, and T. Som. "Inhibition of Cole1RNA primer formationby a plasmid-specified small RNA." *Proc Natl Acad Sci U S A* 78, (1981): 1421-5.
- Udo, E. E., J. W. Pearman, and W. B. Grubb. "Genetic Analysis of Community Isolates of Methicillin-Resistant Staphylococcus Aureus in Western Australia." *J Hosp Infect* 25, no. 2 (1993): 97-108.
- Van Melderren, L., and M. Saavedra De Bast. "Bacterial Toxin-Antitoxin Systems: More Than Selfish Entities?" *PLoS Genet* 5, no. 3 (2009): e1000437.
- Venkateswaran, K., N. Hattori, M. T. La Duc, and R. Kern. "Atp as a Biomarker of Viable Microorganisms in Clean-Room Facilities." *J Microbiol Methods* 52, no. 3 (2003): 367-77.
- Wagner, E. G., and C. Unoson. "The Toxin-Antitoxin System Tisb-Istr1: Expression, Regulation, and Biological Role in Persister Phenotypes." *RNA Biol* 9, no. 12 (2012): 1513-9.
- Wang, X., Y. Kim, S. H. Hong, Q. Ma, B. L. Brown, M. Pu, A. M. Tarone, M. J. Benedik, W. Peti, R. Page, and T. K. Wood. "Antitoxin Mqsa Helps

- Mediate the Bacterial General Stress Response." *Nat Chem Biol* 7, no. 6 (2011): 359-66.
- Wang, X., D. M. Lord, H. Y. Cheng, D. O. Osbourne, S. H. Hong, V. Sanchez-Torres, C. Quiroga, K. Zheng, T. Herrmann, W. Peti, M. J. Benedik, R. Page, and T. K. Wood. "A New Type V Toxin-Antitoxin System Where Mrna for Toxin Ghot Is Cleaved by Antitoxin Ghos." *Nat Chem Biol* 8, no. 10 (2012): 855-61.
- Wang, X., D. M. Lord, S. H. Hong, W. Peti, M. J. Benedik, R. Page, and T. K. Wood. "Type Ii Toxin/Antitoxin Mqsr/Mqsa Controls Type V Toxin/Antitoxin Ghot/Ghos." *Environ Microbiol* 15, no. 6 (2013): 1734-44.
- Wang, X., and T. K. Wood. "Toxin-Antitoxin Systems Influence Biofilm and Persister Cell Formation and the General Stress Response." *Appl Environ Microbiol* 77, no. 16 (2011): 5577-83.
- Williams, J.J., E.M. Halvorsen, E. M. Dwyer, R. M. DiFazio, and P. J. Hergenrother. "Toxin-Antitoxin (TA) Systems are Prevalent and Transcribed in Clinical Isolates of *Pseudomonas aeruginosa* and Methicillin- Resistant *Staphylococcus aureus*." *FEMS Microbiol Lett* 322, no. 1 (2011): 41-50.
- Winn , W.C., E.W. Koneman , S.D. Allen , W.M. Janda , G.W. Procop , P.C. Schreckenberger , and G.L. Woods *Koneman's Color Atlas and Textbook of Diagnostic Microbiology*. Edited by 6th ed. Philadelphia Lippincott Williams & Wilkins., 2006.
- Wladyka , B., W.M. Ilczyszyn , J. Pogwizd , A. Rojowska , N. Malachowa , E. Bonar , K. Polakowska , G. Dubin , and A. Dubin. "Potential Application of Staphylococcal Pch91 Plasmid in Biotechnology." *45th Annual Meeting of the Polish Biochemical Society* 57, no. 4 (2010): 24.
- Wozniak, R. A., and M. K. Waldor. "A Toxin-Antitoxin System Promotes the Maintenance of an Integrative Conjugative Element." *PLoS Genet* 5, no. 3 (2009): e1000439.
- Wunderink, R. G., J. Rello, S. K. Cammarata, R. V. Croos-Dabrera, and M. H. Kollef. "Linezolid Vs Vancomycin: Analysis of Two Double-Blind Studies of Patients with Methicillin-Resistant *Staphylococcus Aureus* Nosocomial Pneumonia." *Chest* 124, no. 5 (2003): 1789-97.
- Yamaguchi, Y., J. H. Park, and M. Inouye. "Toxin-Antitoxin Systems in Bacteria and Archaea." *Annu Rev Genet* 45 (2011): 61-79.
- Zinn , C.S., H. Westh , and V.T. Rosdahl. "The Sarisa Study Group: An International Multicenter Study of Antimicrobial Resistance Andtyping of Hospital *Staphylococcus Aureus* Isolates from 21 Laboratories in 19 Countries or States." *Microb Drug Resist* 10 (2004): 160-68.